Edition:
United Kingdom

John Miller

Swiss drugmaker Roche ups outlook as sales growth offsets price hit

17 Apr 2019

ZURICH Swiss drugmaker Roche lifted its 2019 outlook on Wednesday, as sales growth in China and the United States outpaced price declines it has suffered amid President Donald Trump's pressure on the industry to hold down charges.

Germans in Swiss 'cum-ex' trial given suspended sentences

11 Apr 2019

ZURICH Three Germans on trial in Switzerland for helping expose a tax-stripping scheme that cost European governments billions of euros will likely avoid prison after a verdict on Thursday that fell well short of prosecutors' demands.

Swiss government says coffee 'not essential', stockpiling to end

10 Apr 2019

ZURICH Switzerland on Wednesday announced plans to abolish the nation's emergency stockpile of coffee, in place for decades, after declaring the beans not vital for human survival, though opposition to the proposal is brewing.

Alcon tops $28 billion market cap in decade's biggest Swiss stock deal

09 Apr 2019

ZURICH Swiss eyecare company Alcon made its debut on the SIX Swiss Exchange on Tuesday with a market capitalisation of more than $25 billion after a shareholder spin-off from drugmaker Novartis, the Alpine nation's biggest stock deal in a decade.

Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group

03 Apr 2019

ZURICH Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.

Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group

03 Apr 2019

ZURICH, April 3 Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.

Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI

03 Apr 2019

ZURICH Novartis's spinoff of its eyecare division Alcon, set for Tuesday April 9, marks the largest Swiss stock deal in a decade and forces a reshuffle of the benchmark Swiss Market Index (SMI) as private bank Julius Baer gets booted out.

World News